Insulet Corporation (NASDAQ: PODD) has recently received a number of price target changes and ratings updates:

  • 8/4/2017 – Insulet Corporation had its “outperform” rating reaffirmed by analysts at Cowen and Company. They now have a $63.00 price target on the stock, up previously from $52.00.
  • 8/4/2017 – Insulet Corporation had its “buy” rating reaffirmed by analysts at Northland Securities. They wrote, “Epizyme‚Äôs loss per share of $0.48 was less than our estimated $0.66. This resulted from higher than estimated revenue, which was $10 million compared to our estimated $0.6 million, and resulted from a milestone payment. Expenses were in line with expectations. Our outlook for 2017-22 remains basically unchanged. We are adjusting our 2017 estimates to reflect the milestone payment in this quarter.””
  • 8/4/2017 – Insulet Corporation was given a new $55.00 price target on by analysts at Oppenheimer Holdings, Inc.. They now have a “hold” rating on the stock.
  • 8/1/2017 – Insulet Corporation was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.
  • 7/22/2017 – Insulet Corporation had its “hold” rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
  • 7/20/2017 – Insulet Corporation was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “INSULET CORPORATION is an innovative medical device company dedicated to improving the lives of people with diabetes. The Company’s OmniPod Insulin Management System is a revolutionary, discreet and easy-to-use insulin infusion system that features two easy-to-use components with no tubing and fully-automated cannula insertion. Through the OmniPod System, Insulet seeks to expand the use of continuous subcutaneous insulin infusion (CSII) therapy among people with insulin-dependent diabetes. “
  • 7/18/2017 – Insulet Corporation was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $57.00 price target on the stock. According to Zacks, “INSULET CORPORATION is an innovative medical device company dedicated to improving the lives of people with diabetes. The Company’s OmniPod Insulin Management System is a revolutionary, discreet and easy-to-use insulin infusion system that features two easy-to-use components with no tubing and fully-automated cannula insertion. Through the OmniPod System, Insulet seeks to expand the use of continuous subcutaneous insulin infusion (CSII) therapy among people with insulin-dependent diabetes. “
  • 7/17/2017 – Insulet Corporation was downgraded by analysts at BTIG Research from a “buy” rating to a “neutral” rating.
  • 7/14/2017 – Insulet Corporation had its “buy” rating reaffirmed by analysts at Cowen and Company. They now have a $52.00 price target on the stock.
  • 7/14/2017 – Insulet Corporation had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $48.00 price target on the stock.
  • 7/11/2017 – Insulet Corporation had its “hold” rating reaffirmed by analysts at Canaccord Genuity. They now have a $50.00 price target on the stock, up previously from $42.00.
  • 6/27/2017 – Insulet Corporation was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
  • 6/16/2017 – Insulet Corporation had its “buy” rating reaffirmed by analysts at Jefferies Group LLC.

Insulet Corporation (NASDAQ:PODD) last released its earnings results on Thursday, August 3rd. The medical instruments supplier reported ($0.13) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.13). Insulet Corporation had a negative return on equity of 46.88% and a negative net margin of 7.30%. The company had revenue of $110 million for the quarter, compared to analysts’ expectations of $106.23 million. During the same quarter in the previous year, the firm posted ($0.08) EPS. The firm’s quarterly revenue was up 26.0% on a year-over-year basis.

In other Insulet Corporation news, SVP Michael P. Spears bought 2,500 shares of the company’s stock in a transaction on Tuesday, May 16th. The shares were bought at an average price of $40.59 per share, for a total transaction of $101,475.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Jessica Hopfield bought 2,580 shares of the company’s stock in a transaction on Thursday, May 11th. The shares were acquired at an average price of $38.68 per share, for a total transaction of $99,794.40. The disclosure for this purchase can be found here. Insiders have acquired a total of 8,080 shares of company stock worth $317,339 in the last quarter. 2.60% of the stock is currently owned by insiders.

Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).

Receive News & Ratings for Insulet Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet Corporation and related companies with MarketBeat.com's FREE daily email newsletter.